CONTEXT: Isoliquiritigenin (ISL) has been shown to exhibit a variety of biological activities. However, there is little research on the pharmacokinetic behavior and tissues distribution of ISL. OBJECTIVE: Pharmacokinetics, biodistribution and bioavailability of ISL after intravenous and oral administration were determined by systematic investigation in Sprague-Dawley rats. MATERIALS AND METHODS: ISL was dissolved in medicinal ethanol-Tween 80-0.9% sodium chloride saline in a volume ratio of 10:15:75. The ISL solution was injected in rats via a tail vein at a single dose of 10, 20 and 50 mg/kg and administered orally in rats at a single dose of 20, 50 and 100 mg/kg, respectively. Blood samples were collected at time intervals of 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 6, 8 and 12 h after intravenous injection. Tissues of interests in mice were collected immediately at each determined time point (0.5, 1, 2, 3 and 6 h) after cervical dislocation. RESULTS: The dose-normalized AUC values were 7.3, 7.6 and 8.7 μg × h/ml (calculated based on the dose of 10 mg/kg) for intravenous doses of 10, 20 and 50 mg/kg, respectively. The elimination half-lifes (t1/2λ) were 4.9, 4.6 and 4.8 h at 10, 20 and 50 mg/kg intravenous doses, respectively. The F values were 29.86, 22.70, 33.62% for oral doses of 20, 50 and 100 mg/kg, respectively. Liver, heart and kidney were major distribution tissues of ISL in mice. The plasma protein binding of ISL in rats was 43.72%. CONCLUSION: The work may useful for further study of the bioactive mechanism of ISL.
CONTEXT: Isoliquiritigenin (ISL) has been shown to exhibit a variety of biological activities. However, there is little research on the pharmacokinetic behavior and tissues distribution of ISL. OBJECTIVE: Pharmacokinetics, biodistribution and bioavailability of ISL after intravenous and oral administration were determined by systematic investigation in Sprague-Dawley rats. MATERIALS AND METHODS:ISL was dissolved in medicinal ethanol-Tween 80-0.9% sodium chloride saline in a volume ratio of 10:15:75. The ISL solution was injected in rats via a tail vein at a single dose of 10, 20 and 50 mg/kg and administered orally in rats at a single dose of 20, 50 and 100 mg/kg, respectively. Blood samples were collected at time intervals of 0.08, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 6, 8 and 12 h after intravenous injection. Tissues of interests in mice were collected immediately at each determined time point (0.5, 1, 2, 3 and 6 h) after cervical dislocation. RESULTS: The dose-normalized AUC values were 7.3, 7.6 and 8.7 μg × h/ml (calculated based on the dose of 10 mg/kg) for intravenous doses of 10, 20 and 50 mg/kg, respectively. The elimination half-lifes (t1/2λ) were 4.9, 4.6 and 4.8 h at 10, 20 and 50 mg/kg intravenous doses, respectively. The F values were 29.86, 22.70, 33.62% for oral doses of 20, 50 and 100 mg/kg, respectively. Liver, heart and kidney were major distribution tissues of ISL in mice. The plasma protein binding of ISL in rats was 43.72%. CONCLUSION: The work may useful for further study of the bioactive mechanism of ISL.
Authors: Sang Mi Park; Jong Rok Lee; Sae Kwang Ku; Il Je Cho; Sung Hui Byun; Sang Chan Kim; Sook Jahr Park; Young Woo Kim Journal: Eur J Nutr Date: 2015-11-22 Impact factor: 5.614
Authors: Krystyna Okoniewska; Marek T Konieczny; Krzysztof Lemke; Tomasz Grabowski Journal: Eur J Drug Metab Pharmacokinet Date: 2017-02 Impact factor: 2.441
Authors: Nathan D d'Adesky; Juan Pablo de Rivero Vaccari; Pallab Bhattacharya; Marc Schatz; Miguel A Perez-Pinzon; Helen M Bramlett; Ami P Raval Journal: Int J Mol Sci Date: 2018-04-30 Impact factor: 5.923
Authors: Subhayan Sur; Robert Steele; T Scott Isbell; Kalyan Nagulapalli Venkata; Mostafa E Rateb; Ratna B Ray Journal: Cancers (Basel) Date: 2021-03-21 Impact factor: 6.639